Amgen Inc. $AMGN Stock Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.4% during the third quarter, Holdings Channel.com reports. The fund owned 305,174 shares of the medical research company’s stock after selling 10,877 shares during the period. Russell Investments Group Ltd.’s holdings in Amgen were worth $128,744,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of AMGN. State Street Corp increased its holdings in Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. MW Advisory LLC purchased a new stake in Amgen in the 2nd quarter worth approximately $1,054,000. Baird Financial Group Inc. lifted its holdings in Amgen by 1.6% in the 2nd quarter. Baird Financial Group Inc. now owns 339,825 shares of the medical research company’s stock worth $123,057,000 after buying an additional 5,496 shares during the period. MassMutual Private Wealth & Trust FSB grew its position in shares of Amgen by 105.8% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 13,514 shares of the medical research company’s stock worth $5,696,000 after buying an additional 6,947 shares during the last quarter. Finally, Nilsine Partners LLC bought a new stake in shares of Amgen in the 2nd quarter worth approximately $3,329,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Royal Bank Of Canada upped their target price on Amgen from $430.00 to $470.00 and gave the company an “outperform” rating in a report on Wednesday, November 4th. The Goldman Sachs Group lifted their price target on shares of Amgen from $481.00 to $536.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Freedom Broker downgraded shares of Amgen from a “buy” rating to a “hold” rating and boosted their price objective for the company from $450.00 to $470.00 in a research report on Friday, November 6th. Morgan Stanley raised their target price on shares of Amgen from $359.00 to $410.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. Finally, Bank of America raised their target price on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $424.66.

Get Our Latest Stock Report on AMGN

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $465.67 on Monday. Amgen Inc. has a 52-week low of $312.39 and a 52-week high of $483.99. The firm has a market capitalization of $251.89 billion, a P/E ratio of 27.01, a P/E/G ratio of 3.24 and a beta of 0.43. The stock has a 50 day moving average price of $425.31 and a 200-day moving average price of $381.17. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48.

Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, beating the consensus estimate of $5.79 by $0.66. Amgen had a return on equity of 114.99% and a net margin of 24.14%. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period in the previous year, the company posted $5.64 earnings per share. The firm’s revenue was up 8.5% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen Inc. will post 23.37 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, November 20th. This represents a $10.08 annualized dividend and a yield of 2.2%. Amgen’s dividend payout ratio (DPR) is currently 58.47%.

Amgen Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Read More

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.